Perspective on the economic evaluation of deep brain stimulation by Emma McIntosh
INTEGRATIVE NEUROSCIENCE
This perspective article will begin by introducing the key cost 
and outcome components relevant to DBS and this will be fol-
lowed by specific topics of methodological importance in the DBS 
area related to both costs and benefits. Finally, a discussion will 
be based around the key economic factors that will influence the 
cost-effectiveness of DBS as well as the theoretical and methodo-
logical challenges to using a broad evaluation perspective, with 
particular reference to the importance of measuring outcomes 
in the DBS area.
The idenTificaTion of resource use daTa in dBs
A detailed comparison of patient resource utilization and costs 
of all aspects of DBS surgery and its comparator is crucial in any 
evaluation of DBS. Ideally such data will come from a randomized 
controlled trial (RCT) or other rigorous design. Resource use data 
in DBS are typically related to the resources outlined in Table 1.
hospiTal sTay
In DBS it is predicted that the duration of hospital stay for the 
DBS surgery and any related subsequent events and adverse events 
related to the surgery such as infections will be a significant key 
cost driver of the total cost. It is therefore important to identify 
hospital stay in the economic evaluation as accurately as possible.
inTroducTion
The aim of this paper is to outline issues pertinent to the economic 
evaluation of deep brain stimulation (DBS) with a view to provid-
ing a general framework for future economic evaluations of DBS 
technology whatever the indication. The broad economic issues 
around DBS technology are currently an under researched topic. 
This is due to the lack of evidence from large comparative studies 
but also due to a lack of theoretical consideration of the key range 
of costs and benefits associated with DBS, their long-term impact 
and related methodological considerations. Whilst a number of 
economics publications have contributed to the evidence base in 
this area independently on costs and health-care outcomes in the 
area of Parkinson’s disease (PD) significant gaps remain on the 
“cost-effectiveness” of DBS technology more generally. At present 
Government funding for many health-care procedures such as 
DBS is often based on inaccurate costs and narrow measures of 
benefit. This is partly due to the complexity of costing disease 
treatment pathways and limited vista on the definition of benefits 
used. DBS is no exception to this. It is therefore important to 
have robust evidence on both the short and long-term costs and 
health-care outcomes of DBS interventions. Such information 
allows decision makers to prioritize funding appropriately using 
sound evidence.
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Parkinson’s disease (PD) is an example of a disease area experiencing increasing use of 
deep brain stimulation (DBS) to treat symptoms. PD is a major cause of morbidity and has a 
substantial economic impact on the patients, their caregivers, the health service, and broader 
social and community services. The PDSURG Collaborators Group reported that DBS surgery 
for patients with advanced PD improves motor function and quality of life that medical therapy 
alone at 1 year but there are surgery related side effects in a minority (Williams et al., 2010). 
The aim of this paper however is to build upon the knowledge generated from evaluating 
DBS in PD and to provide a detailed perspective on the economic evaluation of DBS more 
generally with a view to providing a framework for informative design of DBS economic 
evaluations. This perspective will outline the key categories of resource use pertinent to DBS 
beyond the surgical scenario and into the broader aspects of follow-up care, adverse events, 
repeat procedures, social and community care, patient and carer costs, and will explore the 
importance of handling capital costs of DBS equipment appropriately as well as including 
costs occurring in the future. In addition, this perspective article will outline the importance of 
capturing broader aspects of “outcome” or benefits as compared to those traditional clinical 
measures used. The key message is the importance of employing a broad “perspective” on 
the measurement and valuation of costs and benefits as well as the importance of adopting 
the appropriate time horizon for evaluating the costs and benefits of DBS. In order to do this 
effectively it may be that alternative methods of economic evaluation in health care to the 
commonly used cost-effectiveness analysis may have to be used, such as cost-benefit analysis 
(McIntosh et al., 2010).
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dBs equipmenT
As outlined in Table 1 above the different types of equipment 
involved in DBS are: implantable pulse generator (IPG), elec-
trodes, extension leads, patient controller as well as the large 
capital items used by the surgeons, nurses, and electrophysiolo-
gists during the operation such as the stereotactic frame which 
keeps the head still during the DBS operation and the planning 
station used to identify the appropriate coordinates in the brain 
for targeting the electrodes. There are a number of different 
suppliers producing these equipments and generally the prices 
are similar. Due to the high cost of these pieces of equipment 
it is important that they be accurately annuitized as a function 
of lifespan and cost per use estimated based on throughput. A 
paper by Joint et al. (2002) estimated the hardware-related prob-
lems of DBS and noted a 20% rate of hardware-related problems 
in their cohort as compared to a range of 7–65% reported by 
other groups. The cost of the equipment may change over time 
for instance in DBS a new implant has been developed with a 
much longer battery life however the capital cost of this is more 
expensive and currently in the UK only few patients have been 
given this option. Table 2 below gives a summary of the range 
of costs for the DBS equipment.
medicaTion
It is the case in PD that often following DBS surgery patients 
become less reliant on certain forms of medication. The reduction 
in such a cost should be taken into consideration by the economic 
evaluation as a function of time. Drug prices should been calcu-
lated from the net cost used in pricing excluding VAT (For UK 
specific medication costs are obtained from the British National 
Formulary, BNF; Joint Formulary Committee, 2010. Prices should 
reflect the cost per individual patient dosage calculated on a daily 
basis and multiplied by the appropriate time period. In DBS data 
should also be collected on medication change over time to allow 
for the beneficial effects of DBS permitting a reduction in medica-
tion use. Such detailed information on drug use is important in 
the evaluation of DBS as it is the case that whilst the majority DBS 
costs are up front and occur at the time of the surgical episode it 
may be the case that the offset reductions in expensive drugs (e.g., 
Apomorphine in PD) may continue for a number of years and 
give rise to substantial cost savings which, if ignored, could bias 
the economic evaluation. In the situation where long-term data 
are unavailable then the use of economic modeling techniques 
and sensitivity analysis methods are recommended to identify the 
magnitude of savings.
serious adverse evenTs
In DBS in PD some of the more common serious adverse events 
arising following surgery include infections (often caused by break-
through of electrodes), stroke, hemorrhage, DVT (Costs identified in 
Ramzi and Leeper, 2004) and fractures arising from falls following 
DBS (wrist, humerus, pelvic, odontoid). The main cost incurred 
with infections are the cost of hospital stay and antibiotic treatment 
but the costs increase markedly where the infection requires that the 
IPG and electrodes be removed and a new set inserted. Such adverse 
Table 1 | Resource data typical in DBS.
Stage Resource use
Pre-operative Clinic appointments
 Pre-operative assessment: neurology staff
Operative Theater time: neurology staff and consumables
 DBS equipment: implantable pulse generator (IPG); 
 electrodes; leads; extension leads; patient controller
 Planning station
 Stereotactic frame
 Robotic equipment
 Hospital stay (neurology ward)
Post-operative Follow-up clinic appointments
 GP visits
 PD nurse appointments
 Subsequent procedures: theater time,  
 hospital stay, equipment
 Adverse events: all operative resources outlined 
 above; medications (e.g., antibiotics for infections)
All stages Social and community care costs: GP visits; physiotherapy 
 visits; nurse visits; community psychiatric care visits
All stages Patient costs: out of pocket expenses; travel costs 
 attending appointments; medication costs; aids and 
 adaptations; modifications to homes; cleaner costs;  
 gardening costs; home equipment such as special 
 beds/shower units; Loss of Income due to time 
 off work/inability to work
All stages Informal carer costs: time spent caring for PD patient 
 (value of time); loss of income due to time spent caring
All stages Hospital stay
 Institutionalization costs
 Care home costs
 Meals on wheels
 Day centers
All stages Medication/drugs
Table 2 | Approximate costs# of DBS equipment and related planning 
equipment.
Item Cost UK (2008)
Implantable pulse generator £7,000–£8,500
Electrode £800–£900*
Extension lead £700–£850*
Patient controller £600–£700
Accessory kit £75–£100
Planning station £60,0001
Stereotactic frame £75,0002
#Costs provided are approximated based on averages from different suppliers 
and exclude VAT.
*Usual number required for DBS surgery = 2.
1Life span usually 5 years (this cost does not include maintenance costs not take 
into account throughput).
2Life span usually 3 years (this cost does not include maintenance costs nor take 
into account throughput).
Source: personal correspondence with suppliers.
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producTiviTy cosTs and dBs
Productivity costs as defined by the Washington Panel are: “…costs 
associated with lost or impaired ability to work or engage in leisure 
activities due to morbidity and lost economic productivity due to 
death” (Gold et al., 1996). Brouwer et al. (2001) propose an alter-
native definition of productivity costs as “Costs associated with 
production loss and replacement costs due to illness, disability, and 
death of productive persons, both paid and unpaid.” For a compre-
hensive guide to all three methods both theoretically and practically 
as well as a direct comparison of the methods see Pritchard and 
Sculpher (2000), see also (Rice and Cooper, 1967; Koopmanschap 
et al., 1997). Productivity cost are pertinent to DBS as this tech-
nology may enable patients to engage in or indeed return to an 
economically productive life such as returning to a job or engaging 
in valued leisure time once again. As such any economic evaluations 
in the area of DBS should ensure that employment status or daily 
activities are measured accordingly so that the impact of DBS on 
such activities are captured.
Key concepTs in cosTing meThodology used for dBs 
evaluaTions
A “micro” approach to the costing of surgery and medical resources 
uses patient-specific data itemized by use of resources and such an 
approach is useful in early evaluation of new technologies where 
the key cost drivers have yet to be identified. The key cost drivers 
in DBS will ultimately be the high capital costs of the equipment 
which is patient-specific as well as the ward stay and follow-up 
procedures including adverse events and repeat implantations. It 
is recommended that where DBS is being evaluated for the first 
time in a disease area a micro-costing approach be used to identify 
the key cost drivers.
Base year
It is important to identify all costs in the same base year. This may 
require inflation or deflation of some items. The current discount 
rate for annuitization of capital items is 3.5% as recommended by 
HM Treasury (HM Treasury, 2003). Bearing in mind that to get 
to the final “total” cost figure many different variables have to be 
added together and different data points will have differing levels of 
complete data from patients hence missing data should be analyzed 
using appropriate techniques such as multiple imputation methods 
(Van Buuren et al., 1999).
equivalenT annual cosT (eac) of dBs equipmenT cosTs
As outlined in earlier annuitization is an important costing method 
relevant to DBS as a result of the high cost items of equipment used. 
Capital costs tend to occur at a single point in time however, capital 
assets are used over time and can be sold at any time therefore the 
opportunity cost of capital is spread over time. As a consequence of 
this, the appropriate costing of capital items requires the calculation 
of an EAC. This EAC is therefore the capital cost apportioned into 
EACs as a function of expected lifespan and appropriate discount 
rate. In addition to this however to obtain a “unit cost per use” items 
of capital generally also require the inclusion of annual servicing 
and replacement part costs and these “annual costs” should then be 
divided by the annual throughput of patients using the equipment to 
events are likely to be similar across disease areas as they are common 
to the technology rather than the disease hence, the costing for such 
adverse events may be transferable across economic evaluations.
informal care cosTs
The number of carers per patient and the duration of time spent caring 
per week should be collected where possible so that the impact of DBS on 
such “informal care” can be estimated. The informal costs of caring can 
be estimated based on a number of different assumptions for the hourly 
rate of caregivers (Van den berg and Ferrer-I-Cabonell, 2007; De Meijer 
et al., 2010). Informal care can comprise a substantial part of long-term 
care and often substitutes formal home and nursing home care (Van 
Houtven and Norton, 2004). Van Houtven and Norton (2004) show 
that informal care reduces formal health-care use and delays nursing 
home entry. Informal care can be thought of as comprising elements 
such as home keeping, personal care, support with mobility, administra-
tive tasks, and socializing. In health care, unlike the available unit costs 
identifiable for formal care such as those outlined in Table 2, market 
prices for such informal care services often do not exist. For example the 
cost of informal care may not reflect the true societal value of resources 
attributed to this activity (Drummond et al., 2005) and as such “shadow” 
prices or proxy values are used (McIntosh et al., 2010). With health serv-
ices becoming increasingly reliant on informal care and the associated 
shift in costs from the health-care sector to the community, for instance 
through early discharge programs, the substitution of inpatient care with 
ambulatory care and the move toward community care of the mentally 
ill – the greater the importance attached to recognizing and valuing the 
true cost of unpaid inputs. Provision of informal care may also result in 
additional costs (although perhaps not direct financial costs within the 
health-care sector) which should also be incorporated into the value of 
the unpaid input. These additional costs are shown in Table 3. In DBS it 
may be the case that the amount of informal care required by recipients 
is reduced with successful DBS and as such should be incorporated into 
the economic evaluation.
insTiTuTionalizaTions and care home cosTs
Where DBS treatment allows patients to continue staying in their 
own home being cared for by their carers then the avoidance of 
institutionalization and care home costs can be substantial. It 
important therefore that such costs be included in the evaluation of 
DBS – it may be that this gives rise to substantial savings over time.
Table 3 | Additional costs associated with informal care.
Additional “costs” “Shadow” price*
Time spent traveling by patients,  Value of time 
relatives, carers
Time spent waiting for consultation, during Value of waiting time 
consultation, treatment, and rehabilitation Opportunity cost of time
Leisure time lost (if time allocated Value of leisure 
to unpaid activity activities forgone 
involves a displacement of 
non-working time)
*Shadow prices are proxy values where there are no identifiable market prices 
or values.
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The imporTance of Time horizon when evaluaTing dBs 
Technologies
In the UK the National Institute for Health and Clinical Excellence 
(NICE) makes recommendations to the NHS on new and exist-
ing medicines, treatments, and procedures. NICE have devised 
the concept of a reference case which was developed by experts 
in the methodological aspects of economic evaluation. The refer-
ence case, based on that published by Gold et al. (1996) specifies 
the methods considered by the institute to be consistent with an 
NHS objective of maximizing health gain from limited resources. 
Within this reference case the time horizon recommended should 
be long enough to include all relevant costs and outcomes relating to 
the intervention. This is an importance issue for economic evalua-
tion of DBS technologies as it is the case that many of the expensive 
equipment and hospital stay costs are very much “up front” and 
it is possible that the savings in terms of reduced medication and 
other health service costs do not occur till further in the future. 
Likewise additional costs incurred such as replacement IPGs and 
adverse events related to for example, infection, hemorrhage, and 
falls may not happen till later then these costs must be included 
in the economic evaluation to reveal the true economic picture of 
DBS in relation to the next best alternative treatment.
idenTificaTion, measuremenT, and valuaTion of 
healTh economic ouTcomes in dBs
While the majority of this paper so far has been dedicated to the 
identification, measurement, and valuation of resources involved 
in DBS another crucial element to any economic evaluation is 
the identification, measurement, and valuation of outcomes. 
Indeed, it is my opinion that this is an area under researched and 
of great significance to the economic research arena in this area. 
Investigation into the science behind outcomes valuation is not 
always considered by many to be the job of economists who are 
often heralded as “accountant” types however this is far from true. 
Indeed mainstream economists in many disciplines from environ-
mental to transport and health economics have developed sound 
theoretical methodologies for valuing outcomes that are increas-
ingly being used.
measuring healTh ∼qalys and Beyond
The subject of measuring health and disease is the concern of many 
disciplines beyond health economics (Bowling, 1991, 1995), includ-
ing public health, epidemiology, and statistics. In health economics 
it is widely accepted that it is theoretically possible to use numer-
aires such as health state utility to value outcomes (Torrance and 
obtain a unit cost per use. Box 1 below provides a worked example of 
the annuitization of the cost of a stereotactic frame and this annui-
tized cost transformed into a “cost per use” as a function of annual 
service costs, annual replacement parts, and annual utilization rate.
handling uncerTainTy in dBs economic analyses
Briggs (2001) distinguishes among a number of different types of 
uncertainty depending upon whether the data are patient level or 
from decision analytic models. In stochastic analyses such as alongside 
clinical trials they identified four main types of uncertainty: meth-
odological; sampling variation; extrapolation; and generalizability/
transferability. For all types of uncertainty apart from extrapolation, 
where modeling methods are recommended, sensitivity analysis is the 
recommended approach to handling uncertainty. Sensitivity analysis 
is a method whereby various parameters in the analysis are varied 
in order to test the impact on the overall result. The main types of 
sensitivity analysis are one way; multi-way; scenario analysis, thresh-
old analysis, and probabilistic sensitivity analysis (PSA). See Briggs 
(2001), Drummond et al. (2005), and Glick et al. (2007) for fuller 
expositions of these methods. Key parameters influencing the cost 
of DBS and which may make the total cost variable “sensitive” to 
change and therefore impact the overall result of the study include 
the following: source of unit costs; cost perspective; lifespan of capital 
items such as those outlined in Table 2; patient throughput; discount 
rate and annual service and maintenance costs. Box 1 above outlined 
the importance of appropriate methodology to identify the cost per 
use of a stereotactic frame used in DBS. Box 2 below now uses this to 
highlight the importance of sensitivity analysis on key costs in DBS 
based on changing the key assumptions regarding lifespan, through-
put, and annual service and maintenance costs.
Box 1 above showed that the base cost of £668.03 per use was 
estimated based on the following assumptions: lifespan = 3 years; 
annual service cost = £1,036;  annual cost of replacement 
parts = £700 and annual utilization rate = 40. Carrying out the 
sensitivity analysis outlined in Box 2 shows that the cost per use is 
sensitive to changes in lifespan and throughput but less sensitive 
to changes in annual service and maintenance costs. This analysis 
shows that for the stereotactic frame cost involved in DBS, efficiency 
savings could be achieved by increasing its lifespan (albeit incur-
ring some extra maintenance and service costs) and increasing 
the annual throughput of the Frame – this may be achieved by 
diversifying the frame’s use to procedures other than DBS.
Box 1 | Annuitization example of stereotactic frame 
  used in dbs surgery.
Assumption Cost per use (£)
Lifespan of 5 years £430.99
Lifespan of 10 years £253.82
Annual throughput of 20 patients £1,336.07
Annual throughput of 80 patients £334.02
Reducing the annual service and £646.33
maintenance costs by 50%
Box 2 | Sensitivity analysis of DBS stereotactic frame  
  cost assumptions.
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human there is a risk for infection, both at the skin level, and in the 
brain. The batteries in the device will have to be changed requiring 
additional surgery, with the average time to battery replacement 
differing based on the underlying disorder, as well as the stimulation 
settings. As with all surgical procedures, there is a small chance of 
infection, and death from the procedure. To download the patient 
information leaflet used in the DBS in PD study (PDSURG) to see 
how the risks of DBS surgery were described in this context please 
see the PDSURG website (http://www.pdsurg.bham.ac.uk).
Clinicians have seen first-hand how DBS has provided signifi-
cant improvements in QOL for patients with PD, tremor, dystonia, 
and other movement and basal ganglia related brain disorders. 
However as outlined above DBS surgery is not suitable for everyone 
and clinicians we will need to be able to select the best possible 
candidates by making assessments as to those patients who have the 
most favorable risk-benefit ratios and delivering that information 
effectively (Movement Disorders Centre UoF, 2011). Clinicians will 
need to better educate patients about who is a suitable candidate, 
and what they can expect and anticipate from the DBS surgical 
approach to their problems. As outlined by the MDC perhaps the 
biggest risk of surgery is that for patients and families the surgery 
will not meet perceived expectations. Hence it is recommended that 
patients have an in depth consultation with a movement disorders 
neurologist to outline the risks and benefits of DBS. The MDC at 
the University of Florida offers a mnemonic device for PD patients 
interested in DBS to help educate them and alter their perceptions 
to more closely match what is known about anticipated benefits 
of surgery. The future however will also bring about changes in 
risks and benefits as the technology evolves. For instance there 
will be rechargeable devices as well as devices that will work on a 
closed-loop circuit (meaning they will automatically turn on when 
needed).
The imporTance of Broad ouTcome measures in dBs
In DBS the use of QALY’s as a generic measure is recommended 
alongside other relevant clinical measures. However a recurring 
theme across all disciplines attending the BIDS DBS workshop in 
September 2010 was the importance of broad outcome measures 
in DBS to measure and value attributes of importance beyond those 
of pure clinical relevance. Broader, and more complex outcomes 
of DBS such as happiness, dignity, personality change, depression, 
euphoria, social stigma and so on may not be adequately captured 
within clinical measures and may need to rely on broader economic 
measures to “value” them. If a health service such as the provision 
of DBS contributes positively to human wellbeing, it has economic 
value. Whether something contributes to an individual’s wellbeing is 
determined by whether or not it satisfies that individual’s preferences. 
The basic value judgment underlying economic valuation is that 
“preferences count,” although this does not imply that all decisions 
must be made on the basis of what people want. Other factors, such 
as what is morally appropriate, what is ethically acceptable, and what 
is reasonable and practical, should be taken into account, although 
often such factors are less amenable to formal economic analysis. 
Such a concept is crucially important in the economic evaluation of 
DBS as there are a number of ethical, moral, social, and legal factors 
which all play a part in this technology (as outlined by the other 
papers in this special edition). One way of estimating the economic 
Sackett, 1972; Torrance, 1976; Sackett and Torrance, 1978; Torrance 
et al., 1982). Culyer (1989) argued for an “extra welfarist” approach 
to health. Unlike the traditional economic “welfarist” approach 
which measures everything deemed to impact upon a person’s over-
all utility (including health) the task of measuring only changes 
in “health” was advocated in the “extra welfarist” approach, with 
the quality adjusted life year (QALY) as the instrument of choice 
(Williams, 1985; Culyer, 1989). As a consequence, much of the 
health economics literature in recent years has concentrated on 
issues around measuring and valuing preferences for health care 
in non-monetary mediums, i.e., quality of life (QOL; Drummond 
et al., 1987; Buckingham, 1993, 1995; Richardson, 1994). This has 
led to the development of health state valuation measures such as 
QALYs (Williams, 1985). In health economics the QALY is the com-
mon outcome measure employed by health economists alongside 
the many clinical outcomes measures specific to disease areas (such 
as the Hoehn and Yahr, 1967 and PDQ-39 Jenkinson et al., 2008 in 
PD) and measures of clinical effectiveness commonly used in cost-
effectiveness analyses (Drummond et al., 2005). The advantage of 
the generic QALY is its ability to be compared across many disease 
areas allowing cost-utility estimates to be compared. In DBS sur-
gery, given the global acceptance of the QALY as a generic measure 
of QOL (Dolan et al., 1995), with its 150 language translations, it 
would be recommended as a generic measure to be administered 
alongside disease specific measures of relevance to the particular 
condition. The EuroQol Group launched a new EQ-5D-5L (EQ-
5D 5 level) self-complete version in 2009 with the aim of further 
improving the sensitivity and reducing ceiling effects of the exist-
ing EQ-5D-3 level version. This is now available in more than 40 
translations. Future plans include EQ-5D-5L versions in web and 
tablet format (The EuroQol Group, 2011).
risKs in dBs
As outlined earlier, there are a number of risks associated with DBS 
surgery and how these are communicated effectively to patients is 
important. It is often the case with DBS surgery, such as in advanced 
PD that DBS surgery is the only remaining option once medication 
effects have worn off over time. In this situation, for some patients, 
there are little viable alternative treatments. The risks and benefits 
of the surgery must be explained to the patient, often using detailed 
patient information leaflets summarizing the available evidence on 
the risks, side effects, and long-term outcomes of the procedure. 
The University of Florida Movement Disorders Centre (MDC; 
Movement Disorders Centre UoF, 2011) outline the main risks 
occurring during the surgical procedure. One of these risks occurs 
when microelectrodes are inserted into the brain to determine the 
best target location. If a microelectrode, or alternatively the DBS 
lead, punctures a blood vessel it can lead to a stroke or a stroke-
like syndrome which may result in weakness, numbness, sensory 
loss, visual difficulties, or a host of other neurological problems. 
Additionally, patients with cognitive dysfunction may worsen fol-
lowing DBS, and the surgery may affect one of many mood and 
cognitive circuits leading to changes such as depression, laughter, 
memory problems, or other psychiatric, and/or behavioral features. 
Additionally, there is a chance the lead may migrate, or the elec-
trode, connecting wire, or implanted pulse generator may break and 
need to be replaced. Any time a foreign body is implanted into a 
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values attached to non-marketed goods and services is to use a stated 
preference (SP) approach. SP approaches are based on hypotheti-
cal or constructed markets, i.e., they ask people to state what eco-
nomic value they attach to attributes of those goods and services. SP 
methods in the DBS context would reply on health-care researchers 
devising questions about the risks and benefits involved in DBS and 
asking patients or members of the population to make valuations of 
the possible outcomes using money (willingness to pay methods) or 
identify trade-offs related to life expectancy (time-trade off methods) 
or risk of death (standard gamble methods). It is this approach which 
will be relevant to the broad evaluation of economic outcomes in 
DBS as it would permit the valuation of attributes beyond only health 
of importance to patients, as outlined above. In the area of DBS it 
may be that an economic SP measure may afford the measurement 
and valuation of a much broader range of benefits than individual 
clinical specific or disease specific measures are able to.
dBs and The capaBiliTy approach
One developing approach in health economics that may be suited 
to such broader evaluation of DBS outcomes is the capability 
approach (Sen, 1993). As outlined more recently by Coast et al. 
(2008b) the capability approach advocates the evaluation of 
programs or interventions on the basis of the extent to which 
a person is able (has the capability) to function in a particular 
way. Given this, the capability approach offers a potentially much 
richer set of dimensions for evaluation. Nussbaum (2003) has 
drawn up a list of 10 central human capabilities comprising life, 
bodily health, bodily integrity, senses, imagination and thought, 
emotions, practical reason, affiliation, other species, play and 
control over one’s environment. Indeed research using capabili-
ties to develop a measure of outcome relevant to older people in 
the UK (ICECAP-O) looks promising as it contains attributes 
of direct relevance to the older population such as attachment, 
security, role, enjoyment, and control (Grewal et al., 2006; Coast 
et al., 2008a). The capabilities approach may be pertinent to DBS 
surgery in many areas as there are broader impacts than simply 
“health” per se with such surgery. The human capabilities  outlined 
above such as bodily integrity, emotions, and control over one’s 
 environment can easily be linked to say the outcomes from DBS 
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discussion
In providing a perspective on the economic evaluation of DBS this 
article has attempted to cover the key topics of specific economic 
relevance to DBS pertinent to all indications. These key topics 
include the importance of appropriate handling of DBS equipment 
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DBS. In addition to this the article has outlined the importance of 
adopting the use of broader outcome measures to allow the true 
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and their carers. It may be the case that newer developments such as 
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